StockData

Insmed vs Liquidia

INSM and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and LQDA compare

Insmed is the larger company, worth 5.3 times as much as Liquidia ($26.7B against $5.1B).

Liquidia grew revenue faster over the last twelve months (2234% versus 240% for Insmed).

Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −39.9% at Insmed.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMLQDA
Size and price
Market cap$26.7B$5.1B
Share price$121.86$56.73
Change, 1 year−36.9%102%
Change, 5 years321%1280%
Beta (5Y)0.841.00
Employees1,664216
StockData Score
Total score88
Valuation score00
Growth score3 (better)2
Performance score23 (better)
Health score33
Dividend score00
Valuation
P/E–40.8×
P/S17.6×11.3× (better)
P/B36.8×26.0× (better)
EV/EBITDA–28.2×
P/FCF–33.7×
FCF yield−2.3%3.0% (better)
Fair value$61.10$32.46
Margin of safety−99.5%−74.8% (better)
Growth
Revenue growth (TTM)240%2234% (better)
Revenue growth, 5Y average29.8%192% (better)
Profitability
Gross margin84.4%–
Operating margin−37.1%37.4% (better)
Net margin−39.9%30.7% (better)
FCF margin−41.3%33.4% (better)
Return on equity−72.5%132% (better)
Financial health
Debt / equity0.76–
Interest coverage−6.9×6.3× (better)
Current ratio2.86 (better)2.31
Altman Z-score7.4210.49 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%81.1%
Held by insiders0.89%19.5%
Insider net buying, 12 months−$133M (better)−$227M
Superinvestors holding1–
Short interest, % of float6.5%24.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.